Mobile Site ›

Interpretive Handbook

‹ Back to index | Back to list | More information

Test 8008 :
Beta-Galactosidase, Fibroblasts

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Beta-galactosidase is a lysosomal enzyme responsible for catalyzing the hydrolysis of beta-galactosides. A deficiency of this enzyme is implicated in the following conditions: GM1 gangliosidosis, Morquio syndrome B, and galactosialidosis. In the first 2, only beta-galactosidase is deficient. Galactosialidosis, however, is the result of a combined deficiency of beta-galactosidase and neuraminidase secondary to a defect in the cathepsin A protein due to a mutation in the CTSA gene. All 3 are autosomal recessive lysosomal storage disorders.     GM1 gangliosidosis can be classified into 3 subtypes that vary with respect to age of onset and clinical presentation. Type 1, or infantile onset, typically presents between birth and 6 months with a very rapid progression of hypotonia, dysostosis multiplex, hepatosplenomegaly, central nervous system (CNS) degeneration, and death usually by 1 to 2 years. Type 2 is generally classified as late infantile or juvenile with onset between 7 months and 3 years presenting with developmental delays and a slower progression. Type 3 is an adult or chronic variant with onset between 3 and 30 years and is typically characterized by slowly progressive dementia with Parkinsonian features and dystonia. The overall incidence has been estimated to be 1 in 100,000 to 200,000 live births.   Mucopolysaccharidosis type IVB (MPS IVB, Morquio B) is one disease in the group of disorders collectively called the mucopolysaccharidoses, which are caused by the deficiency of any of the enzymes involved in the stepwise degradation of dermatan sulfate, heparan sulfate, keratan sulfate, or chondroitin sulfate (glycosaminoglycans [GAGs]). Accumulation of GAGs (previously called mucopolysaccharides) in lysosomes interferes with normal functioning of cells, tissues, and organs. Clinical features and severity of symptoms of MPS IVB are widely variable ranging from severe disease to an attenuated form that generally presents at a later onset with a milder clinical presentation. In general, symptoms may include coarse facies, short stature, enlarged liver and spleen, hoarse voice, stiff joints, and cardiac disease, but no neurological involvement. Treatment options are limited to symptomatic management.   Galactosialidosis can be classified into 3 subtypes that vary with respect to age of onset and clinical presentation. Typical clinical presentation is coarse facial features, cherry-red spots, or skeletal dysplasia. The early infantile form is associated with fetal hydrops, skeletal dysplasia, and early death. The late infantile form typically presents with short stature dysostosis multiplex, coarse facial features, hepatosplenomegaly, and/or heart valve problems. The juvenile/adult form is typically characterized by progressive neurologic degeneration, ataxia, and/or angiokeratomas. The incidence of the juvenile/adult form is greater in individuals with Japanese ancestry.   A diagnostic workup in an individual with GM1 gangliosidosis, Morquio B, or galactosialidosis typically demonstrates decreased beta-galactosidase enzyme activity in leukocytes and/or fibroblasts. Individuals with galactosialidosis would also have decreased neuraminidase activity in leukocytes and/or fibroblasts, in addition to decreased beta-galactosidase enzyme activity. Molecular sequence analysis of GLB1 allows for detection of the disease-causing mutations in affected patients with GM1 gangliosidosis and /or Morquio B, and sequencing of CTSA allows for detection of disease-causing mutations in patients with galactosialidosis.

Useful For Suggests clinical disorders or settings where the test may be helpful

Diagnosis of GM1 gangliosidosis, Morquio syndrome B, and galactosialidosis

Interpretation Provides information to assist in interpretation of the test results

Beta-galactosidase is deficient in GM1 gangliosidosis and Morquio syndrome B. The deficiency of beta-galactosidase combined with neuraminidase deficiency is characteristic of galactosialidosis.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

This test is not suitable for carrier detection.

 

Leukocytes are the preferred specimen for the diagnosis of GM1 gangliosidosis.

 

Because beta-galactosidase is decreased in 3 clinically distinct disorders, a careful review of the clinical findings is necessary to differentiate between GM1 gangliosidosis and Morquio syndrome B. Patients with galactosialidosis will also exhibit decreased neuraminidase values in addition to decreased beta-galactosidase.

 

Interfering factors include lack of viable cells, bacterial contamination, failure to transport tissue in an appropriate media, excessive transport time, and exposure of the specimen to temperature extremes (freezing or >30 degrees C).

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

> or =7.11 nmol/min/mg protein

Clinical References Provides recommendations for further in-depth reading of a clinical nature

1. Suzuki Y, Sakuraba H, Oshima A: Beta-galactosidase deficiency (GM1 gangliosidosis, Morquio's syndrome type B). In The Metabolic Basis of Inherited Disease. Vol 2. Seventh edition. Edited by CR Scriver, AL Beaudet, WS Sly, et al. New York, McGraw-Hill Book Company, 1995, pp 2785-2838

2. Brunetti-Pierri N, Scaglia F: GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects. Mol Genet Metab 2008 Aug;94(4):391-396

3. Caciotti A, Garman SC, Rivera-Colon Y, et al: GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings. Biochim Biophys Acta 2011 Jul;1812(7):782-790


Key